Daily pill to block cortisol offers hope for older people with dementia
Resumen detallado
A daily drug for Alzheimer’s did not benefit everyone in a pivotal clinical trial. But it was a different story for older patients.
A once-a-day pill that reduces levels of the stress hormone cortisol in the brain is offering hope to older people living with Alzheimer’s disease, with early trial results revealing it may slow progression of the disease by up to 30 per cent.
Emestedastat, developed under the brand name Xanamem, works by blocking production of cortisol in key areas of the brain linked to the progression of the disease.
The trial, involving 247 patients in Australia and the US with mild to moderate disease over a 36-week course of treatment, did not record a statistically significant benefit in the overall trial group.
However, participants aged over the median age of 75 – representing half of the group – experienced a slowing of progression of the disease by 30 per cent by the end of the trial.
Dr Steven Gourlay, CEO of Australian biotech company Actinogen, which is developing the drug, said the results in over-75s compared favourably with those of recently approved monoclonal antibody treatments for Alzheimer’s, which reduce progression by between 22 and 27 per cent.
“Nobody’s really developing anything for the older patients who are a bit more severe and more advanced,” he said. “Our drug probably is having an effect of lowering inflammation in the brain because patients who are older also have higher markers of inflammation.”
He acknowledged it was disappointing the drug didn’t show the same benefit in younger patients, but pointed to the benefits of a low-dose oral tablet that would cost significantly less and have fewer side effects than current therapies.
Professor Michael Woodward, honorary medical adviser for Dementia Australia, said it was typical for dementia drug trials to have mixed results, but the findings could help shape the next phase of trials.
“We know that cortisol is really important for dementia,” he said. “And we know that blocking it is a way of preventing some of the changes we see in Alzheimer’s.”
Inicio del artículo, extracto de Brisbane Times. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.brisbanetimes.com.au)




